Menu Search
Equities

Repligen Corp

RGN:MUN

Repligen Corp

Actions
  • Price (EUR)155.90
  • Today's Change-1.65 / -1.05%
  • Shares traded81.00
  • 1 Year change+14.13%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

  • Revenue in USD (TTM)638.76m
  • Net income in USD41.58m
  • Incorporated1981
  • Employees1.78k
  • Location
    Repligen CorpBUILDING 1, SUITE 100, 41 SEYON STREETWALTHAM 02453United StatesUSA
  • Phone+1 (781) 449-9560
  • Fax+1 (302) 655-5049
  • Websitehttps://www.repligen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RGEN:NSQ since
announced		Transaction
value
Metenova ABDeal completed26 Sep 202326 Sep 2023Deal completed4.77%--
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.